

Commercial/Healthcare Exchange PA Criteria
Effective: October 2nd, 2019

Prior Authorization: Drizalma Sprinkle

Products Affected: Drizalma Sprinkle (duloxetine) delayed release oral capsules

Medication Description: Duloxetine hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI).

Covered Uses:

1. Major Depressive Disorder in adults
2. Generalized Anxiety Disorder in adults and pediatric patients 7 years to 17 years old
3. Diabetic Peripheral Neuropathy in adults
4. Chronic Musculoskeletal Pain in adults

Exclusion Criteria:

1. Concomitant use with an MAOI, including linezolid or IV methylene blue, or within 14 days of discontinuing an MAOI; at least 5 days should elapse after discontinuation of duloxetine before MAOI initiation due to risk of serotonin syndrome

Required Medical Information:

1. Diagnosis
2. Previous medications tried/failed
3. Current therapy regimen

Age Restrictions:

Generalized Anxiety Disorder: 7 years of age and older

Major Depressive Disorder, Diabetic Peripheral Neuropathy, Chronic Musculoskeletal Pain: 18 years of age and older

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria:

1. Patient has a diagnosis of Major Depressive Disorder, Diabetic Peripheral Neuropathy, Chronic Musculoskeletal Pain, OR Generalized Anxiety Disorder; AND
2. Patient has a documented intolerance, contraindication, or treatment failure with an adequate trial of generic duloxetine capsules; AND
3. Patient is unable to ingest duloxetine due to one for the following:
 - a. Oral/motor difficulties; OR
 - b. Dysphagia

References:

1. Product Information: DRIZALMA SPRINKLE^(TM) oral delayed-release capsules, duloxetine oral delayed-release capsules. Sun Pharmaceuticals Industries Inc (per FDA), Cranbury, NJ, 2019.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	11/8/2019